A substantially increased number of atypical moles in the setting of a CDKN2A mutation has been termed familial atypical mole and malignant melanoma syndrome (FAMMM), although it is also called the familial melanoma and pancreatic cancer syndrome (FMPC) or the familial atypical multiple mole melanoma-pancreatic carcinoma syndrome (FAMMPC), because of the increased risk of pancreatic cancer [12–18]. Here, CDKN2A is linked to pancreatic neoplasm.